October 30, 2024

Blog

PumasAI is Set to Revolutionize Pharmacometrics and Clinical Pharmacology with the Launch of AskPumas and DeepPumas

PumasAI is Set to Revolutionize Pharmacometrics and Clinical Pharmacology with the Launch of AskPumas and DeepPumas

New AI and machine learning tools created to speed decision-making in drug development  

DOVER, Del. (October 30, 2024) –  PumasAI, a science-first organization dedicated to empowering innovation in drug development, today announced the launch of two transformative products: AskPumas and DeepPumas. Representing the first-ever intersection of AI and biosimulation, these tools are engineered to redefine pharmacometrics, clinical pharmacology, and data science.

With unprecedented predictive capabilities and seamless user integration, AskPumas and DeepPumas are designed to bridge data gaps and streamline workflows across departments, paving the way for more efficient and insightful drug development solutions. 

DeepPumas Allows Hybrid Modeling for Rich, Patient-Specific Predictions

Now available for public use, DeepPumas is set to change the landscape of drug development and patient outcome predictions. This powerful tool combines mechanistic and data-driven modeling, allowing pharmaceutical industry professionals to utilize their scientific understanding of a system while leveraging machine learning to capture complex and previously unknown relationships in patient data.

DeepPumas delivers significant advantages by enabling collaboration between departments — particularly between pharmacometrics and data science teams — while enhancing the ability to extract insights from complex datasets.

Key benefits of DeepPumas include the following:

  • Enhanced Data Utilization: DeepPumas enhances prediction capabilities with effective use of patient data for personalized predictions. 
  • Faster Model Development: This tool accelerates the process of model development and hypothesis generation through its combined knowledge- and data-driven approach. 
  • Flexibility for Big and Small Data: DeepPumas is equipped to handle both large and small datasets, overcoming the limitations of purely mechanistic models. 
  • Realistic Clinical Simulations: The tool allows for the simulation of realistic clinical trial populations by learning the conditional distribution of complex patient responses. 
  • Comprehensive Outcome Predictions: DeepPumas takes machine learning beyond simple metrics by providing rich, individualized time courses of patient outcomes based on complex covariates. 

With DeepPumas, we are making scientific machine learning integrated with statistics more accessible to the pharmaceutical industry and extending it to address the specific challenges of longitudinal data at the same time,” said Dr. Vijay Ivaturi, Co-Founder and CEO of PumasAI. “After proving itself in beta with real-world customers, this hybrid approach has opened new doors for patient-specific insights and therapeutic outcomes at PumasAI and it will do the same for those that engage with it."  

AskPumas: Your AI “Asked and Answered” Industry Friend 

The AskPumas tool introduces a novel approach to utilizing Retrieval Augmented Generation (RAG) technology within the healthcare space. Pharmacometricians and clinical pharmacologists can now seamlessly access a wealth of curated and up-to-date resources with this tool while ensuring data privacy and relevance to specific needs. Designed for flexibility and ease of use, AskPumas provides a robust value-add for organizations seeking powerful AI-driven insights without compromising sensitive data.

Key features of AskPumas include the following:

  • Private and Secure Data Integration: AskPumas enables secure use of private data without it leaving the organization, ensuring maximum utility and security. 
  • Curated Knowledge Resources: Through its constantly updated, focused resource base, the tool provides more relevant answers than generic large language models (LLMs). 
  • Flexibility and Customization: Users can easily extend AskPumas by integrating private knowledge sources, making it highly customizable to meet specific business needs. 
  • Improved Accuracy: By focusing on reducing hallucinations and ensuring human verification of AI responses, AskPumas provides reliable, source-backed information. 

"AskPumas is more than just an AI assistant; it’s like a trusted partner for tackling the toughest questions in our field," said Dr. Ivaturi. "Created by pharmacometricians for pharmacometricians, it mirrors how we work while ensuring user data remains private and secure. This is a pivotal tool for professionals in complex pharmacometric environments, and we're excited to see how far it will drive our industry forward. And this is only the beginning—with our upcoming Workflow Agents, users can expect productivity to double.

A Leap Forward in Scientific AI 

With DeepPumas and AskPumas, PumasAI is delivering on its promise of AI meets biosimulation, marking a monumental leap in scientific innovation. These groundbreaking tools, crafted by experts within PumasAI, set a new standard for advanced collaboration and insight-driven workflows across healthcare and pharmaceutical industries. As these tools integrate into the daily workflows of professionals worldwide, PumasAI stands at the forefront, not just keeping pace with the future of biosimulation— but creating it. 

AskPumas and DeepPumas will be available for preview during the American Conference on Pharmacometrics (ACoP) 2024 annual conference in Arizona this November. For more information about DeepPumas, AskPumas, and how these tools can revolutionize your organization's approach to scientific modeling and AI integration, visit https://pumas.ai/our-products.

About Pumas-AI

PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software and AI tools developed by the company includes the Pumas® suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle, and Lyv, a clinical decision support system that leverages patient history and targeted medical data for personalized healthcare delivery. Scientists at PumasAI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more.

For additional information, visit www.pumas.ai  

Media Contact

Don McLean, McLean Media 734-716-4182


twitter

In other News...

PRESS RELEASE
A Journey of Passion and Innovation: Launching DeepPumas and AskPumasIn the world of tech, product launches are usually accompanied by discussions about cutting-edge algorithms, sleek interfaces, and revolutionary breakthroughs. But for me, the story of DeepPumas and AskPumas is not just about the technology—it’s about the people. It’s about how a global team, spread across 18 countries, came together to build something extraordinary.

In other News...

PRESS RELEASE
Collaborative work by Pumas-AI and Otsuka to be presented at NKF '21We are excited to announce that the collaborative work performed by Otsuka Pharmaceutical Development & Commercialization and Pumas-AI scientists will be presented at National Kidney Foundation 2021 on April 6-10, 2021! The modeling used Pumas software to explore urine osmolality and GFR relationship. Urine Osmolality (Uosm) Is a Reasonable Marker of Acute (TKV) and Longer-term...

In other News...

PRESS RELEASE
Congrats to Dr. Rackauckas – awarded 2020 ISoP Emerging Scientist!Dr. Christopher Rackauckas, our Director of Scientific Research, was recently awarded for the 2020 ISoP Emerging Scientist Award. The International Society of Pharmacometrics (ISoP) Awards Ceremony was hosted by the Eleventh American Conference of Pharmacometrics (ACoP11) on Monday, November 9, 2020. The Emerging Scientist Award, the highest early career award given by ISoP, was granted to...

In other News...

PRESS RELEASE
Dr. Vijay Ivaturi Announced as New Chief Executive Officer at PumasAIThe PumasAI Board of Directors are pleased to announce that, effective Jan 1, 2024, Dr. Vijay Ivaturi will be stepping into the role of Chief Executive Officer, succeeding Dr. Joga Gobburu. After four years of dedicated leadership, Dr. Gobburu will be transitioning from his current role as CEO to the position of Chairman of the Board of PumasAI. Dr. Ivaturi brings a wealth of experience...

In other News...

PRESS RELEASE
Former BMS Quality Director Joins Pumas-AI Scientists as Head of Quality Assurance and Compliance Amid 3X Growth PeriodPumas-AI, a science-first organization that turns data into life-saving decisions faster, announced today that Peter J. Miller has joined the organization as Head of Quality Assurance and Compliance. In his role, Mr. Miller will further strengthen and build upon the quality of deliverables and products that Pumas-AI scientists produce, including clinical pharmacology, pharmacometrics...

In other News...

PRESS RELEASE
Former Bristol-Myers Squibb Head of Pharmacometrics Dr. Amit Roy Joins PumasAI to Support Drug Development Programs and DeepPumas ApplicationPumasAI, a science-first organization that turns data into life-saving decisions faster, announced today that Dr. Amit Roy, former Executive Director and Head of Pharmacometrics at Bristol-Myers Squibb (BMS), has joined PumasAI as Distinguished Scientist. In his new role, Dr. Roy will contribute to PumasAI’s growth trajectory by providing model-informed drug development (MIDD) expertise to accelerate drug development programs...

In other News...

PRESS RELEASE
How Machine Learning Will Change the Future of Pharmaceuticals: Q&A with CEO Joga GobburuThe machine learning market is estimated to be worth a staggering $106.52 billion by the year 2030, according to Market Research Future. Combine this with the rise of consumer interest in artificial intelligence (AI) tools like ChatGPT, the world is beginning to mainstream these technologies. As this occurs, scientists are developing tools to level-up drug development analytics to create stronger outcomes and potentially save more lives...

In other News...

PRESS RELEASE
International Society of Pharmacometrics Names Pumas-AI Co-Founder Dr. Vijay Ivaturi as President-ElectCo-Founder and Chief Scientific Officer (CSO) Vijay Ivaturi, PhD, has been elected as the next President of the International Society of Pharmacometrics (ISoP). Dr. Ivaturi will serve a one-year term as President-Elect effective immediately and will assume the ISoP presidency in January 2024, for a two-year term. As President-Elect, Dr. Ivaturi will oversee the development of ISoP’s three-year strategic plan...

In other News...

PRESS RELEASE
Model-Informed Drug Development: Everything You Need to KnowAccording to the U.S. Food & Drug Administration (FDA), “model-informed drug development (MIDD) is an approach that involves developing and applying exposure-based, biological and statistical models derived from preclinical and clinical data sources to inform drug development and decision-making.” In 2018, the FDA created a pilot program to explore MIDD further...

In other News...

PRESS RELEASE
New Clinical Pharmacology Desktop Software Launched by Pumas-AI is Easier to Use and Compliant with Global RegulationsPumas-AI, a science-first organization that turns data into life-saving decisions faster, announced today that it has launched Pumas-CP - a new clinical pharmacology platform for non-compartmental analysis (NCA), bioequivalence analysis, and pharmacokinetic and pharmacodynamic (PK/PD) modeling. “Pharmacokineticists and clinical pharmacologists are looking for a simple tool to manage...

In other News...

PRESS RELEASE
Pharmacometrician Receives Lewis B. Sheiner Lecturer Award for Outstanding Lifetime AchievementsJoga Gobburu, PhD, a professor in the Department of Practice, Sciences, and Health Outcomes Research (P-SHOR) and director of the Center for Translational Medicine (CTM), received the Lewis B. Sheiner Lecturer Award, the highest recognition from ISoP on Nov. 5 at the society’s annual meeting at the National Harbor in Maryland.

In other News...

PRESS RELEASE
The Future of Modelling and Simulations in Pharmacometrics with JuliaPharmacometricians have been early adopters of mathematical programming tools. We use tools that allow us to solve real problems. However, given the diversity of problems that we solve, our field has seen a split in the languages that we use due to the problems they are tailored to solve...

In other News...

PRESS RELEASE
Powerful Pumas Software is Now Available for Desktop DownloadPumas-AI, a science-first organization that turns data into life-saving decisions faster, announced today that its Pumas software is now available for desktop download. Pumas is a one-stop integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle, turning data into life-saving decisions faster.

In other News...

PRESS RELEASE
Pumas-AI Continues to Expand Pharmaceutical Pharmacokinetics and Clinical Pharmacology Expertise with New Head of Business DevelopmentPumas-AI, a science-first organization that turns data into life-saving decisions faster, announced today that Dhanashri Gudi, Ph.D. has joined the company’s senior leadership team as Head of Business Development to continue to drive the year-over-year double-digit growth that Pumas-AI has experienced since inception. Dr. Gudi has spent nearly 20 years in the pharmaceutical industry, focused on drug metabolism...

In other News...

PRESS RELEASE
Pumas-AI Hires Dr. Salim Bouchene and Expands Consulting Practice in EuropeThis new hire highlights expansions that Pumas-AI has made across the globe in recent years. As a senior scientist, Dr. Bouchene will focus on modeling and simulation and their application to pharmaceutical drug development. He will support Pumas-AI’s global client base through pharmacometrics and clinical pharmacology consulting, PK/PD modeling of clinical and preclinical data across various therapeutic areas...

In other News...

PRESS RELEASE
Pumas-AI Launches Julia Language-Based Software to Advance Drug Development, Patient CarePumas-AI – a new company established by University of Maryland School of Pharmacy faculty members Vijay Ivaturi, PhD, assistant professor in the Department of Pharmacy Practice and Science (PPS), and Joga Gobburu, PhD, MBA, professor in PPS – is proud to announce the release of its first cutting-edge software platform for pharmaceutical researchers and clinicians. Known as Pharmaceutical...

In other News...

PRESS RELEASE
Pumas-AI looks to democratize access to drug development toolsThe University of Maryland, Baltimore startup recently completed a big upgrade for its 2.0 version. Here's why the cofounders say it matters for science, and healthcare. For the cofounders of University of Maryland, Baltimore startup Pumas-AI, technology has the power to democratize access to advanced tools. The startup’s pharmaceutical modeling and simulation platform has two products...

In other News...

PRESS RELEASE
PumasAI Maintains Strong Growth Trajectory with New Product Engineering and Pharmacometrics Hires from JuliaHub and PfizerPumasAI, a pioneering organization at the forefront of transforming data into life-saving decisions with remarkable speed, is proud to announce the appointment of two distinguished leaders to its team. These strategic hires illustrate PumasAI’s dedication to accelerating the translation of complex data into impactful, life-saving strategies and solutions...

In other News...

PRESS RELEASE
PumasAI Named Best Clinical Pharmacology Technology Development Firm in Biotechnology AwardsPumasAI, a science-first organization and a trailblazer in clinical pharmacology technology, has been honored as the “Best Clinical Pharmacology Technology Development Firm” at the prestigious Biotechnology Awards, hosted by Global Health & Pharma. This accolade highlights PumasAI’s significant contributions to the pharmaceutical industry through its innovative approach and dedication

In other News...

PRESS RELEASE
PumasAI Now Offering its Modeling and Simulation Software Free to Academic Research InstitutionsPumas-AI Inc, a science-first organization that turns data into life-saving decisions faster, announced today that it is now opening its powerful modeling and simulation software to all global academic institutions and researchers free of charge. This pro-bono program provides the use of the Pumas® tool, a high-performance analytical software suite that allows users to perform all pharmaceutical modeling and...

In other News...

PRESS RELEASE
Researchers establish Pumas-AI, launch Pumas pharmaceutical softwarePumas-AI, a new company established by University of Maryland School of Pharmacy faculty members Vijay Ivaturi, PhD, assistant professor in the Department of Pharmacy Practice and Science, and Joga Gobburu, PhD, MBA, professor in the department, is proud to announce the release of its first...

In other News...

PRESS RELEASE
The story of PumasAt the outset, I would like to acknowledge and thank all those who contributed to development of Pumas. Here is a complete list in no particular order: Chris Rackauckas; Simon Byrne; Andreas Noack; Patrick Mogensen; José Bayoán Santiago Calderón; Yingbo Ma; Vaibhav Dixit; Xingjian Guo...

In other News...

PRESS RELEASE
UMB-born startup launches pharmaceutical modeling platform Pumas 1.0A startup launched out by faculty at University of Maryland, Baltimore and MIT researchers collaborated to launch Pumas 1.0, a predictive analytics platform that aids in the development cycle of pharmaceutical drugs. What that means is Pumas 1.0 takes the data a drug company has and simulates the success rate or possible outcome of a drug. Creating models and simulations through the algorithm...

In other News...

PRESS RELEASE
UMB Grants Pumas-AI Exclusive License for Lyv, a Cutting-Edge Clinical Decision Support SystemPumas-AI, a University of Maryland, Baltimore (UMB) startup company, has been granted worldwide, exclusive rights to Lyv, a cutting-edge clinical decision support system designed to help health care professionals personalize treatment trajectories for patients in real-time. The Lyv platform leverages clinical research and Electronic Health Record (EHR) data from millions of patients to derive…

In other News...

PRESS RELEASE
UMB Startup Pumas-AI Receives Exclusive LicensePumas-AI, a University of Maryland, Baltimore (UMB) startup company, has been granted worldwide, exclusive rights to enhancements to Pumas, an end-to-end pharmaceutical modeling and simulation platform for quantitative analysis across the drug development lifecycle. Pumas 2.0 builds on the company’s existing platform, which also employs technology licensed from UMB...

In other News...

PRESS RELEASE
University of Maryland, Baltimore Researchers' Startup, Pumas-AI, Launches Cutting-Edge Healthcare SoftwarePumas-AI, a new University of Maryland, Baltimore (UMB) startup company established by University of Maryland School of Pharmacy (SOP) faculty members Vijay Ivaturi, PhD, assistant professor, and Joga Gobburu, PhD, MBA, professor, has released its first, cutting-edge software platform for pharmaceutical researchers and clinicians. Known as Pharmaceutical Modeling and Simulation (Pumas), the s...

Leading businesses, research labs and universities choose us as their healthcare intelligence partners.

PumasAI News and Events
PumasAI.svg
Pumas-AI Inc.
3500 South Dupont Highway
Suite GT-101
Dover, DE 19901
Email: info@pumas.ai
twittertwitter
Pumas-AI Inc.
3500 South Dupont Highway
Suite GT-101
Dover, DE 19901
Email: info@pumas.ai
twittertwitter

© Pumas-AI Inc. 2024. All rights reserved.